Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Iterum Therapeutics ( (ITRM) ).
On August 25, 2025, Iterum Therapeutics plc received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company has 180 days, until February 23, 2026, to regain compliance by ensuring its share price meets the $1.00 minimum for 10 consecutive business days. Failure to comply could lead to delisting, although the company may qualify for an additional compliance period or appeal any delisting decision.
The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.
Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Average Trading Volume: 778,060
Technical Sentiment Signal: Sell
Current Market Cap: $30.51M
For an in-depth examination of ITRM stock, go to TipRanks’ Overview page.